Randomized Phase 2/3 Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

Principal Investigator

Dr Mark Henry Tuthill

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1014270